Success Metrics

Active Trials

4(50%)

Phase Distribution

Ph not_applicable

25%

Ph phase_4

38%

Ph phase_1

13%

Ph phase_2

13%

Ph phase_3

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

1(12.5%)

Phase 2Efficacy & side effects

1(12.5%)

Phase 3Large-scale testing

1(12.5%)

Phase 4Post-market surveillance

3(37.5%)

N/ANon-phased studies

2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Detailed Status

Not yet recruiting4

Recruiting4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 4

Trials by Phase

Phase 11 (12.5%)

Phase 21 (12.5%)

Phase 31 (12.5%)

Phase 43 (37.5%)

N/A2 (25.0%)

Trials by Status

not_yet_recruiting450%

recruiting450%

Recent Activity

4 active trials

Showing 5 of 8

not_yet_recruitingphase_4

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

NCT07014540

recruitingnot_applicable

Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.

NCT06894797

not_yet_recruitingphase_4

Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer

NCT06499610

recruitingphase_4

Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer

NCT06467786

not_yet_recruitingnot_applicable

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

NCT06463548

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT07014540Phase 4

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

Not Yet Recruiting

NCT06894797Not Applicable

Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.

Recruiting

NCT06499610Phase 4

Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer

Not Yet Recruiting

NCT06467786Phase 4

Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer

Recruiting

NCT06463548Not Applicable

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

Not Yet Recruiting

NCT06430827Phase 2

Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Not Yet Recruiting

NCT06340204Phase 1

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Recruiting

NCT06128837Phase 3

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Recruiting

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8